← All trials
NCT01817556
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2012
- Primary completion
- Oct 1, 2013
- Completion date
- Oct 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 258
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Dong-A PharmaceuticalLead sponsor
- Ajou UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Chungnam National UniversityOverall official - principal investigator
- Dongguk UniversityOverall official - principal investigator
- Konkuk UniversityOverall official - principal investigator
- Konyang UniversityOverall official - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Inje UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Soonchunhyang UniversityOverall official - principal investigator
- Pusan National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.